Overview

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

Status:
Not yet recruiting

Trial end date:
2027-01-31

Target enrollment:

Participant gender:

Summary

This study aims to utilize a novel biomarker-driven approach to guide neoadjuvant treatment selection. It is the hypothesis that this will improve clinical response for postmenopausal women with clinical stage II/III ER-positive, HER2-negative breast cancer and identify those who may not require neoadjuvant chemotherapy, with a primary focus on outcomes in Black patients.

Phase:

Phase 2

Details

Lead Sponsor:

Washington University School of Medicine

Treatments:

Anastrozole
Taxane